TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~F506-CL-0404 Part A~* Subject was ≤12 years of age at enrolment into study F506-CL-0403~* Subject received at least one dose of Modigraf in the F506-CL-0403 study~F506-CL-0404 Part B~* Subject received at least one dose of Modigraf in the F506-CL-0403 study~* Subject participated in F506-CL-0404 Part A~* Subject has continuously been dosed with Twice daily (BID) Modigraf since the End of Study Visit for Part A (ESVA) from F506-CL-0404 Part A~* Subject is stable and has had no dose changes in the preceding 2 weeks~Exclusion Criteria:~F506-CL-0404 Part A~* As all subjects included in this study conform to the exclusion criteria in study F506-CL-0403, hence no specific exclusion criteria are relevant for this study~F506-CL-0404 Part B~* There are no specific exclusion criteria for this study

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Part A: Heart Transplant (Tacrolimus granules) (Type: EXPERIMENTAL): In Part A of the study, participants who are heart transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
- Part A: Liver Transplant (Tacrolimus granules) (Type: EXPERIMENTAL): In Part A of the study, participants who are liver transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
- Part A: Kidney Transplant (Tacrolimus granules) (Type: EXPERIMENTAL): In Part A of the study, participants who are kidney transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
- Part B: All Participants (Tacrolimus capsules) (Type: EXPERIMENTAL): In Part B of the study, participants who are heart, kidney or liver transplant recipients and who are converted from tacrolimus granules-based immunosuppression regimen, receive tacrolimus capsules twice daily for 1 month and thereafter receive commercially available tacrolimus capsules.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Determination of the Iodine Status in Pregnant Women in the Netherlands.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female~* 18-45y old~* in first 16 weeks of pregnancy~* pregnant of singleton~Exclusion Criteria:~* Thyroid-disease or any other metabolic disease~* kidney disease~* twin-pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Total cohort (Type: None): No intervention, all participants undergo the same measurements

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combined Phacoemulsification With iStent Inject W Versus Hydrus for Mild to Moderate Open Angle Glaucoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>60 years or older~* Visually significant cataract~* Mild to moderate primary open angle glaucoma controlled on medications~* undergoing cataract surgery with lens implantation and concurrent microstent placement~* IOP ≥ 21 mmHg and ≤ 36 mmHg after washout of ocular hypotensive medication(s)~* CCT 480 to 620μm~* No prior ocular surgery including corneal refractive surgery~* No SLT within 6 months of baseline visit, no history of intracameral glaucoma drug eluting implants~* Visual field mean deviation ≤ -12 dB~* Optic nerve abnormalities consistent with glaucoma, C/D ratio less than ≤0.8~Exclusion Criteria:~* Prior intraocular surgery~* Visual field MD ≥ -12 dB~* secondary glaucoma including uveitis, traumatic, malignant, neovascular, and congenital glaucoma.~* Glaucoma related to elevated episcleral venous pressure including Sturge-Weber syndrome, thyroid eye disease, orbital tumor, and etc.~* Uncontrolled intraocular pressure on maximum tolerated medical therapy;~* Unable to perform wash-out IOP~* Anatomic exclusion of narrow anterior chamber angle (Shaffer grade I-II), other angle abnormalities including angle closure glaucoma~* Corneal disease or dystrophy~* Pathological myopia with degeneration that affects diagnostic imaging~* Clinically significant ocular pathology or degenerative diseases that affect vision, visual field, or optical coherence tomography of optic nerve.~* Inability to perform reliable Visual Field and optical coherence tomography.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Combined cataract surgery with Hydrus microstent (Type: ACTIVE_COMPARATOR): None
- Combined cataract surgery with iStent Inject W (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with HCC Patients can be included if they require treatment prior to liver transplantation.~* Barcelona Clinic Liver Cancer Stage System class A-B~* One to three tumors of maximum cumulative diameter ≤ 6 cm measured in all 3 axes.~* Measurable disease to be selected as a target on CT/MRI-scan, according to mRECIST criteria for HCC within 6 weeks prior to randomization (≥ 1cm at least in one dimension, suitable for repeated measurement, and arterial enhancement) \[44\].~* Tumor visibility on CT~* Child-Pugh A cirrhosis~* Age ≥ 18 years~* ECOG performance status 0-1~* Albumin\> 28 g/l, bilirubin \< 50 µmol/l, INR \< 2.3, AST/ALT \< 5 times ULN, within 6 weeks prior to randomization~* Platelets will be preferably ≥ 50x10E9/ l (if not, thrombocytes transfusion is allowed to ensure a safe procedure at the discretion of the interventional radiologist and gastroenterologist). Leukocytes \> 1.5x10E9/l, Hb \> 6 mmol/l, within 6 weeks prior to randomization~* Written informed consent~* Willing and able to comply to the follow-up schedule~* Planned to start treatment within 6 weeks from randomization.~Exclusion Criteria:~* Eligibility for resection or RFA~* More than three tumors in the liver~* Ascites~* Any signs of acute viral or non-viral hepatitis~* Encephalopathy~* Vascular tumor invasion (contact with the vessel will not be considered contraindication).~* Previous radiotherapy to the liver~* Known current pregnancy~* Distance from the tumor to the esophagus, stomach, duodenum, small bowel or large bowel \< 0.5 cm on CT or on MRI (randomization imaging). Depending on the SBRT technique used, the minimum acceptable distance may vary and be larger for one technique compared to the other~* Uncontrolled portal hypertension (high bleeding risk). If gastroscopy has been performed, untreated esophageal varices grade III or IV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transarterial chemoembolization (Type: ACTIVE_COMPARATOR): Chemoembolization will be performed through a transarterial route delivering drug eluting beads, i.e. hydrogel-based microspheres (Biocompatibles UK, Ltd, HepaSphere Biosphere Medical) loaded with the chemotherapeutic agent doxorubicin.
- Stereotactic body radiation therapy (Type: EXPERIMENTAL): Risk-adapted dose prescription for delivering the highest possible tumor dose not exceeding the maximum dose in 6 fractions of 8-9 Gy, while hepatic normal tissue complication probability (NTCP) \< of 5%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female infant born at \>36 weeks of gestation and aged 2 months (42 to 98 days) at the time of consent (the day of birth is considered day of life 1).~* Healthy infant determined by medical history, physical examination, and clinical judgment.~Exclusion Criteria:~* Previous vaccination with licensed or investigational pneumococcal vaccine.~* Prior receipt of routine pediatric vaccines, with the exception of hepatitis B vaccine.~* Previous receipt of \>1 dose of hepatitis B vaccine.~* Prior hepatitis B vaccine must have been administered at age \<30 days.~* Major known congenital malformation or serious chronic disorder.~* Receipt of blood/plasma products or immunoglobulins.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 98 Days
- Healthy Volunteers: t

Study Arms:
- Group 1 - Coadministration (Type: EXPERIMENTAL): Multivalent pneumococcal conjugate vaccine coadministered with Prevnar 13
- Group 2 - Staggered Administration (Type: EXPERIMENTAL): Multivalent pneumococcal conjugate vaccine given 1 month after Prevnar 13
- Group 3 - Control with Supplemental Dose (Type: ACTIVE_COMPARATOR): Prevnar 13 with a single dose of multivalent pneumococcal conjugate vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Analgesia Nociception Index Guided Remifentanil Administration During Propofol Anesthesia for Laparoscopic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* laparoscopic cholecystectomy or gynecological laparoscopic surgery~* ASA I or II~* adult patient~* body mass index between 17 and 33 kg/m2~Exclusion Criteria:~* pregnancy~* arrhythmia~* pace maker~* diabetes mellitus~* dysautonomia~* treatment with beta blocking agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ANI guided remifentanil arm (Type: EXPERIMENTAL): remifentanil targets are increased or decreased depending on ANI readings. In case of high blood pressure associated with elevated ANI, nicardipine is administered.
- ANI blind arm (Type: OTHER): remifentanil target is adapted as is usual during general anesthesia, depending on hemodynamic reactions to nociceptive surgical stimulations. In case of elevated blood pressure despite a maximum target of 10 ng/ml (Minto Pk/pD model), then nicardipine is administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HbA1c: 7.5-11.0% on current therapy~* OHA (oral hypoglycaemic agent) treatment for a minimum of two years~* BMI (body mass index): 25-32 kg/m2

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients or their health care proxies must be able to provide consent to participate in this trial.~* Patients must have one of the following diagnoses which has not responded or recurred following at least one prior chemotherapy regimen or radiation therapy:~  * anaplastic astrocytoma, glioblastoma multiforme or oligodendroglioma~ * primary CNS lymphoma~ * malignant disease metastatic to the CNS~* Patients must be candidates for high dose chemotherapy and autologous stem cell transplant according to the following criteria:~  * Patients must be between the ages of 18 and 70 years (inclusive)~ * Patients must have a left ventricular ejection fraction greater than or equal to 45% by MUGA or echocardiogram~ * Patients must have adequate pulmonary function with FEV1, FVC and DLCO greater than or equal to 50% of predicted~ * Patients must have serum direct bilirubin less than or equal to 2.0 mg/dl and transaminases less than or equal to 3x institutional upper limit of normal~ * Patients must have serum creatinine less than or equal to 2 mg/dl with creatinine clearance greater than or equal to 60 ml/min (either calculated or measured)~ * Patients must have an ECOG performance status between 0 and 2~* Patients must be at least 4 weeks from last cytoreductive chemotherapy.~* Expected survival of at least 3 months~Exclusion Criteria:~* Patients with uncontrolled metastatic disease outside of the CNS which would itself, in the investigator's opinion, limit survival to less than 6 months~* Patients with uncontrolled seizures are ineligible.~* Patients with a history of myocardial infarction within the preceding 6 months, significant arrhythmia within the preceding 3 months, or uncontrolled hypertension or congestive heart failure are ineligible.~* Patients with unstable angina are ineligible.~* Pregnant or lactating women are ineligible.~* Male and female patients who do not agree to practice approved methods of birth control for the duration of the study are ineligible.~* Patients with uncontrolled, active infection are ineligible.~* Patients infected with HIV are ineligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Navigated Transcranial Magnetic Stimulation in Monitoring Stroke Recovery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* one sided ischemic stroke confirmed by radiology~* 20-80 years old~Exclusion Criteria:~* hemorrhagic stroke~* brainstem stroke~* cerebellar stroke~* thalamic stroke~* seizure with the recent stroke~* any history of uncontrolled seizure~* history of epilepsy~* pregnancy or planning on getting pregnant during the next year~* MRI incompatibility (e.g. metal implants in body)~* recent history (past year) of alcohol and drug abuse (due to lack of follow up)~Other criteria include TMS exclusions: aneurysm clips, previous surgery over motor cortex, open craniotomy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Navigated TMS (Type: None): single arm study where all subjects will be studied using the Navigated TMS device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Hoehn \& Yahr stage I\~III~* Patients with idiopathic Parkinson's disease(PD), who meet the United Kingdom Parkinson's Disease Society Brain Bank diagnostic criteria, with a good response to levodopa~* The onset of PD symptoms must be occurred \> = 40 years of age (to exclude YOPD), and the patient must have been diagnosed with idiopathic PD \> =40 years of age~* Patients may have symptoms of wearing OFF and/or levodopa induced dyskinesia~* Patients must rate between Hoehn \& Yahr stage I to III, when in an OFF medication state~* Patients must in their optimal medication treatment state, and will not changing their medications within 3 months before and after enrollment~Exclusion Criteria:~* Patients who are proved to be Young Onset Parkinson's Disease (YOPD) and/or genetically related (e.g. Parkin).~* Women of child-bearing potential, pregnant or lactating.~* Patients who are proved to have tumor growth and/or malignancy.~* Patients with a past (within one year) or present history of psychotic symptoms requiring anti- psychotic treatment.~* Patients with active symptoms of major depression with suicidal ideation or suicide attempt.~* Patients with previous brain surgery (including pallidotomy and deep brain stimulation).~* Patients with significant cognitive impairment ( Mini-Mental State Examination, MMSE \< 24).~* Patients who do not sign the inform consent,

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- high dose G-CSF (Type: EXPERIMENTAL): high dose group: 3.3ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
- low dose G-CSF (Type: ACTIVE_COMPARATOR): low dose group: 1.65ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
- placebo (Type: PLACEBO_COMPARATOR): Sodium Chloride (NaCl) 0.9 %

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for individuals with Bipolar Disorder (BD)~1. Men and women aged 18-55 years (extremes included).~2. Able to provide informed consent in English.~3. A diagnosis of BD type I or BD type II and good physical health.~4. Current euthymic state for at least 4 weeks.~Inclusion Criteria for Healthy Control (HC) individuals:~1. Men and women aged approximately 18-55 years (extremes included).~2. Able to provide informed consent in English.~3. No psychiatric diagnoses and in good physical health.~General exclusion criteria:~1. Cannabis naïve~2. Unwillingness to remain alcohol-free, cannabis-free for at least 1 week (in infrequent cannabis users) prior to each test day.~3. Evidence of a hearing deficit.~4. IQ less than 80.~5. Positive pregnancy test, lactation, and refusal to practice birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Active 4 mg inhaled THC (Type: EXPERIMENTAL): Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
- Active 2 mg inhaled THC (Type: EXPERIMENTAL): Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
- Placebo (Type: PLACEBO_COMPARATOR): Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Establishment of a PDT Patient Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All adult patients (≥ 18 years of age) treated with PDT.~* Women and men and members of all races and ethnic groups.~* Subjects may have received prior treatment for their cancer.~* Subjects to give a written informed consent for prospectively collected data.~Exclusion Criteria:~* None.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues